Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 131-142

  Yerushalmi, Rinat ^a   Gelmon, Karen A ^a   Leung, Samuel ^b   Gao, Dongxia ^b   Cheang, Maggie ^c   Pollak, Michael ^d   Turashvili, Gulisa ^e   Gilks, Blakes C ^f   Kennecke, Hagen ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e Department of Molecular Oncology ^*  (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basal like, HER2; IGF 1R, breast cancer; Insulin like growth factor receptor; Subtypes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P27; SOMATOMEDIN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84857920393     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1529-8     Document Type: Article

References (64)

1. Kasuya J, Paz IB, Maddux BA et al (1993) Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. Biochemistry 32:13531-13536 (Pubitemid 24020228)
2. Pandini G, Vigneri R, Costantino A et al (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5:1935-1944 (Pubitemid 29334478)
3. Adams TE, Epa VC, Garrett TP et al (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093 (Pubitemid 30598754)
4. Shang Y, Mao Y, Batson J et al (2008) Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 7:2599-2608
5. Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:423-429
6. Werner H, Maor S (2006) The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 17:236-242 (Pubitemid 44080616)
7. Ouban A, Muraca P, Yeatman T et al (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34:803-808 (Pubitemid 37040618)
8. Law JH, Habibi G, Hu K et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246
9. Shimizu C, Hasegawa T, Tani Y et al (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35:1537-1542 (Pubitemid 40017995)
10. Railo MJ, von Smitten K, Pekonen F (1994) The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311 (Pubitemid 24152469)
11. Papa V, Gliozzo B, Clark GM et al (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740 (Pubitemid 23252035)
12. Shin A, Ren Z, Shu XO et al (2007) Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 105:55-61 (Pubitemid 47282744)
13. Bonneterre J, Peyrat JP, Beuscart R et al (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50:6931-6935 (Pubitemid 20361093)
14. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28:3009-3021
15. Blum G, Gazit A, Levitzki A (2000) Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39:15705-15712 (Pubitemid 32038232)
16. Garcia-Echeverria C, Pearson MA, Marti A et al (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5:231-239 (Pubitemid 38402115)
17. Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230 (Pubitemid 38402114)
18. Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12:589-603 (Pubitemid 351699478)
19. Stephen RL, Shaw LE, Larsen C et al (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 276:40080-40086
20. Sachdev D, Singh R, Fujita-Yamaguchi Y et al (2006) Downregulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66:2391-2402
21. Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921 (Pubitemid 38064071)
22. Pandini G, Wurch T, Akla B et al (2007) Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43:1318-1327 (Pubitemid 46720250)
23. Sachdev D, Drug evaluation (2007) CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer. Curr Opin Mol Ther 9:299-304
24. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485-498
25. Schillaci R, Salatino M, Cassataro J et al (2006) Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8? response involving Fas/Fas ligand cytotoxic pathway. J Immunol 176:3426-3437 (Pubitemid 43363990)
26. Capodanno A, Camerini A, Orlandini C et al (2009) Dysregulated PI3 K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 40:1408-1417
27. Charpin C, Giusiano S, Secq V et al (2009) Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol 34:983-993
28. Vendrell JA, Robertson KE, Ravel P et al (2008) A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res 10:R88
29. Bremer TM, Jacquemier J, Charafe-Jauffret E et al (2009) Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. Int J Cancer 124:896-904
30. Fleming ID, Cooper JS, Henson DE et al (1997) AJCC Cancer Staging Manual, 5th edn. Lippincott-Raven, Philadelphia
31. Bearhs OH, Henson DE, Hutter RVP et al (1992) AJCC Cancer Staging Manual, 5th edn. Lippincott-Raven, Philadelphia
32. Cheang MC, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644 (Pubitemid 46631303)
33. Voduc D, Cheang M, Nielsen T (2008) GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 17:365-373 (Pubitemid 351272788)
34. Mulligan AM, O'Malley FP, Ennis M et al (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39-47 (Pubitemid 47498088)
35. Hakam A, Fang Q, Karl R et al (2003) Coexpression of IGF-1R and c-src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 48:1972-1978 (Pubitemid 37410086)
36. Power KA, Chen JM, Saarinen NM et al (2008) Changes in biomarkers of estrogen receptor and growth factor signaling pathways in MCF-7 tumors after short- and long-term treatment with soy and flaxseed. J Steroid Biochem Mol Biol 112:13-19
37. Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481 (Pubitemid 29220854)
38. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
39. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376 (Pubitemid 351413917)
40. Nielson TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
41. Rajput AB, Turbin DA, Cheang MC et al (2008) Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4, 444 cases. Breast Cancer Res Treat 107:249-257 (Pubitemid 350265695)
42. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252-7259 (Pubitemid 39487712)
43. Govindarajulu US, Malloy EJ, Gangali B et al. (2009) The comparison of alternative smoothing methods for fitting nonlinear exposure-response relationships with cox models in a simulation study. Int J Biostat 5. doi: 10.2202/1557-4679.1104
44. McShane LM, Altman DG, Sauerbei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
45. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100:237-238 (Pubitemid 44631926)
46. Robert A, Toupance B, Tremblay M et al (2009) Impact of inbreeding on fertility in a pre-industrial population. Eur J Hum Genet 17:673-681
47. Creighton CJ, Fu X, Hennessy BT et al (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER? breast cancer. Breast Cancer Res 12:R40. doi:101186/bcr2594
48. Creighton CJ, Casa A, Lazard Z et al (2008) Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078-4085
49. Chu IM, Hengst L, Slingerland JM (2008) The cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253-267 (Pubitemid 351430863)
50. Esparis-Ogando A, Ocana A, Rodriguez-Barrueco R et al (2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 19:1860-1869
51. Binder C, Marx D, Overhoff R et al (1995) Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 6:1005-1010 (Pubitemid 26015247)
52. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198 (Pubitemid 24345666)
53. Lee KH, Im SA, Oh DY et al (2007) Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 7:63
54. Haluska P, Carboni JM, TenEyck C et al (2008) HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7:2589-2598
55. Chakraborty AK, Welsh A, Digiovanna MP (2010) Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 120:327-335
56. Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 13:471-483
57. Guix M, Faber AC, Wang SE et al (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118:2609-2619 (Pubitemid 351949788)
58. Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:BR521-6 (Pubitemid 36119174)
59. Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814 (Pubitemid 40065552)
60. Nahta R, Yuan LX, Zhang B et al (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128 (Pubitemid 41713383)
61. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst 93:1852-1857 (Pubitemid 34048651)
62. Kaufman PA, Ferrero JM, Bourgeois H et al (2010) A randomized, double-blind, placebo-controlled, phase 2 study of AMG- 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone receptor positive (HR?) metastatic (M) or locally advanced (LA) breast cancer. In: San Antonio breast cancer symposium, CTRC-AACR, San-Antonio, Texas, December 2010
63. Pitts TM, Tan AK, Kulikowski GN et al (2010) Development of an integrated genomic classifier for novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 16:3193-3204
64. Yee D (2010) How to train your biomarker. Clin Cancer Res 16:3091-3093